Literature DB >> 28357807

Dual MicroRNA to Cellular Prion Protein Inhibits Propagation of Pathogenic Prion Protein in Cultured Cells.

Sang-Gyun Kang1,2, Chiye Kim1,3, Judd Aiken1,2, Han Sang Yoo4, Debbie McKenzie5,6.   

Abstract

Prion diseases are fatal transmissible neurodegenerative disorders affecting humans and various mammals. In spite of intensive efforts, there is no effective cure or treatment for prion diseases. Cellular forms of prion protein (PrPC) is essential for propagation of abnormal isoforms of prion protein (PrPSc) and pathogenesis. The effect of an artificial dual microRNA (DmiR) on PrPC suppression and resultant inhibition of prion replication was determined using prion-infectible cell cultures: differentiated C2C12 culture and primary mixed neuronal and glial cells culture (MNGC). Processing of DmiR by prion-susceptible myotubes, but not by reserve cells, in differentiated C2C12 culture slowed prion replication, implying an importance of cell type-specific PrPC targeting. In MNGC, reduction of PrPC with DmiR was effective for suppressing prion replication. MNGC lentivirally transduced with non-targeting control miRNAs (scrambled) reduced prion replication at a level similar to that with a synthetic analogue of viral RNA, poly I:C. The results suggest that a synergistic combination of the immunostimulatory RNA duplexes (miRNA) and PrPC silencing with DmiR might augment a therapeutic potential of RNA interference.

Entities:  

Keywords:  Differentiated C2C12 cells; Immune stimulator; Neuronal and glial cells; Prion disease; Therapeutic RNAi

Mesh:

Substances:

Year:  2017        PMID: 28357807     DOI: 10.1007/s12035-017-0495-5

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  56 in total

Review 1.  Prions.

Authors:  David W Colby; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

Review 2.  A general model of prion strains and their pathogenicity.

Authors:  John Collinge; Anthony R Clarke
Journal:  Science       Date:  2007-11-09       Impact factor: 47.728

3.  Eight prion strains have PrP(Sc) molecules with different conformations.

Authors:  J Safar; H Wille; V Itri; D Groth; H Serban; M Torchia; F E Cohen; S B Prusiner
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440

4.  The disease characteristics of different strains of scrapie in Sinc congenic mouse lines: implications for the nature of the agent and host control of pathogenesis.

Authors:  M E Bruce; I McConnell; H Fraser; A G Dickinson
Journal:  J Gen Virol       Date:  1991-03       Impact factor: 3.891

5.  Mice devoid of PrP are resistant to scrapie.

Authors:  H Büeler; A Aguzzi; A Sailer; R A Greiner; P Autenried; M Aguet; C Weissmann
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

Review 6.  Molecular mechanisms of prion pathogenesis.

Authors:  Adriano Aguzzi; Christina Sigurdson; Mathias Heikenwaelder
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

7.  Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent.

Authors:  R A Bessen; R F Marsh
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Normal host prion protein necessary for scrapie-induced neurotoxicity.

Authors:  S Brandner; S Isenmann; A Raeber; M Fischer; A Sailer; Y Kobayashi; S Marino; C Weissmann; A Aguzzi
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

Review 9.  Rational targeting for prion therapeutics.

Authors:  Giovanna Mallucci; John Collinge
Journal:  Nat Rev Neurosci       Date:  2005-01       Impact factor: 34.870

10.  Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.

Authors:  Giovanna Mallucci; Andrew Dickinson; Jacqueline Linehan; Peter-Christian Klöhn; Sebastian Brandner; John Collinge
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

View more
  5 in total

1.  Inability of DNAzymes to cleave RNA in vivo is due to limited Mg[Formula: see text] concentration in cells.

Authors:  Julian Victor; Gerhard Steger; Detlev Riesner
Journal:  Eur Biophys J       Date:  2017-12-16       Impact factor: 1.733

Review 2.  Identification of anti-prion drugs and targets using toxicity-based assays.

Authors:  Robert Cc Mercer; David A Harris
Journal:  Curr Opin Pharmacol       Date:  2019-01-23       Impact factor: 5.547

Review 3.  Regulation of MicroRNAs-Mediated Autophagic Flux: A New Regulatory Avenue for Neurodegenerative Diseases With Focus on Prion Diseases.

Authors:  Syed Zahid Ali Shah; Deming Zhao; Tariq Hussain; Naveed Sabir; Lifeng Yang
Journal:  Front Aging Neurosci       Date:  2018-05-15       Impact factor: 5.750

4.  MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives.

Authors:  Eirini Kanata; Katrin Thüne; Konstantinos Xanthopoulos; Isidre Ferrer; Dimitra Dafou; Inga Zerr; Theodoros Sklaviadis; Franc Llorens
Journal:  Front Aging Neurosci       Date:  2018-07-23       Impact factor: 5.750

Review 5.  MicroRNAs in Prion Diseases-From Molecular Mechanisms to Insights in Translational Medicine.

Authors:  Danyel Fernandes Contiliani; Yasmin de Araújo Ribeiro; Vitor Nolasco de Moraes; Tiago Campos Pereira
Journal:  Cells       Date:  2021-06-29       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.